MAP2K7 and head and neck squamous cell carcinoma: In addition, the list of top-ranked candidates with a higher sensitivity for SChigh HNSCC included EGFR inhibitors (e.g., Canertinib, AST-1306) and MEK inhibitors (e.g., Refametinib).